Taipei Medical University (TMU) and Merck Sharp & Dohme (MSD) Taiwan have entered into a Memorandum of Understanding to cooperate in six major directions to promote healthcare in Taiwan.
This collaboration, the first large-scale cooperation between a global pharmaceutical company and a medical university in Taiwan, will infuse international resources into Taiwan's healthcare innovation system and strengthen its biotechnology and pharmaceutical competitiveness.
TMU Office of Business Development will establish the 'MSD Innovative Strategic Partnership' with industry professionals at MSD to offer business guidance, clinical validation, and co-working with startups.
TMU Office of Human Research will collaborate with clinical trial professionals at MSD to upgrade clinical trial capabilities at TMU's affiliated hospitals to increase efficiency.
TMU Office of Academic Affairs will collaborate with MSD human resource professionals to design practical industry-oriented curricula for TMU students with the objectives of integrating scholastic knowledge with practical skills and enhancing international exposure for Taiwanese young talent.
TMU Office of Data Science will collaborate with MSD clinico-marketing professionals to build real-world evidence (RWE) initiatives. TMU Center for Management and Development will set up an 'Expedited New Drug Pathway' to expedite access to innovative medicines, particularly first-in-class innovative drugs which had undergone clinical trials in TMU's 3,000-bed medical systems.
TMU Taipei Cancer Center will integrate the Enhanced Recovery After Surgery (ERAS) programs and streamline patient pathways to provide early diagnosis and early treatment.
